This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’s PFE hemophilia ...

A late-breaking clinical trial has shown that muvalaplin, an innovative oral medication, can safely and effectively lower ...

Ruth Gimeno, Lilly's group vice president for diabetes and metabolic research, said Eli Lilly is weighing next steps for ...

Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 ...

The trials include: KRAKEN, a randomised phase 2 trial of Muvalaplin, the first oral drug that targets Lipoprotein(a) particles BROOKLYN, which is investigating the safety and efficacy of Obicetrapib ...

Melbourne researchers are helping expand options for people with high cholesterol that puts them at risk of heart attack or stroke, including world-first drugs for potentially deadly conditions.

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the ...

BMO Capital notes that Silence Therapeutics (SLN) is trading significantly lower following AHA updates due to concerns that favorable data from ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein (a) or Lp (a) levels in adults with high risk of cardiovascular events in a ...

"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...

Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with ...

American Heart Association Scientific Sessions 2024, Abstract 4171286 - The oral medication muvalaplin may safely lower high ...